What are the leading pharmaceutical manufacturing stocks?
Leading antibiotic stocks are stocks of publicly traded companies that have a leading position in the antibiotic industry. These companies have an edge in developing, manufacturing and marketing antibiotic drugs, benefiting from the growing global demand for healthcare and the trend of an aging population. The following is a list of leading pharmaceutical manufacturing stocks.
What are the leading stocks in pharmaceutical manufacturing
The leading stocks in pharmaceutical manufacturing are: 600085 Tongrentang, 000538 Yunnan Baiyao, 600771 Tibet Pharmaceuticals, 600285 Antelope Shares, 000423 Dong'a Gum, 000650 Renhe Pharmaceuticals, 600422 Kunming Pharmaceutical, 600771 Dongsheng Technology, 000597 Northeast Pharmaceuticals, 600829 Sanjing Pharmaceuticals, 600812 North China Pharmaceuticals, 600488 Tianyao Pharmaceuticals, 002019 Xinfu Pharmaceuticals, 600252 Zhongheng Group, 600276 Hengrui Pharmaceuticals, 000952 Guangji Pharmaceuticals and so on.
What are the leading influenza pharmaceutical stocks
1, Hengrui Medicine 600276 (total pharmaceutical stock leader, anti-tumor drug leader)
2, Yunnan Baiyao 000538 (total Chinese medicine leader)
3, Myriad Medical 300760 (medical device leader)
4, WuXi KangDe 603259 (new drug trial leader)
5, Tonghua Dongbao 600867 (diabetes leader)
6, Colom Pharmaceutical 002422 (I.V. leader)
7, Xinhecheng 002001 (vitamin drugs leader)
8, Renfu Medicine 600079 (anesthesia leader)
9, Hualan Bio 002007 (the largest influenza virus vaccine production base, plasma leader)
10, Changchun High-tech 000661 (growth hormone leader)
11, Enhua Pharmaceuticals 002262 (central nervous system leader)
12, Aier Ophthalmology 300015 (ophthalmic services leader)
13, Tongze Medical 600763 (oral dental services leader)
14, Qizheng Tibetan medicine 002287 (paste medicine leader)
15, Dongcheng Pharmaceutical 002675 (nuclear medicine leader)
16, Shanghai Pharmaceuticals 601607 (pharmaceutical business leader)
17, TEDA 000652 (masks leader)
18, Fish Leap Medical 002223 (home medical equipment leader)
19, Dabo medical 002901 (orthopedic materials leader)
20, Lepu medical 300003 (cardiac stent leader)
21, Shandong Pharmaceutical Glass 600529 (medicinal glass leader)
22, Contagious Biological 300601 (vaccine leader)
23, LUXEMBOURG Medical 002223 (home medical equipment leader)
18, TEDA 000652 (mask leader)
23, Lunan Pharmaceutical 600789 (antibiotic drug leader)
24, Tigermed 300347 (clinical CRO leader)
25, Meinian Health 002044 (physical examination business leader)
26, AnTuTu Bio 603658 (chemiluminescent diagnostic reagent leader)
27, Jianfan Bio 300529 (blood perfusion device leader)
28, Yifeng Pharmacy 603939 (pharmacy leader)
29, I Wu Biological 300357 (anti-allergy biopharmaceuticals leader)
30, Huada Genetics 300676 (genetic testing leader)
31, in the source of the Concordia 600645 (with China's only stem cell industrialization base)
29, I Wu Biological 300357 (anti-allergy biological drugs leading)
30, Huada Genetics 300676 (genetic testing leading)
30, Zhongyuan Concordia 600645 (has China's only stem cell industrialization base)< /p>
The next is Yiming organized 32 low price-earnings ratio, earnings per share is greater than 0.5 yuan!
Pharmaceutical Stocks Leading Stocks Ranked Top 10
Pharmaceutical stock segments include APIs, chemical agents, biological agents, medical services, medical devices, medical business and many other areas.
One, the API industry: VE, VA leading Xinhecheng, VB5 leading Yifan Pharmaceuticals, VB2 leading Guangji Pharmaceuticals, VC leading North China Pharmaceuticals, Northeast Pharmaceuticals, etc., VD3 leading Garden Biologicals, antibiotic APA leading Federal Pharmaceuticals, Corticosteroid leading Xianju Pharmaceuticals.
Second, chemical agents: oncology drug leader Hengrui Medicine, hypertension sartanopril class leader Huahai Pharmaceuticals, liver disease leader China Biopharmaceuticals, heparin leader Heparin, peptide leader Hanyu Pharmaceuticals.
Three, biologics: three generations of insulin leader Gan & Lee Pharmaceuticals, the second generation of insulin leader Tonghua Dongbao, blood products leader Hualan Bio, vaccine leader Contagious Bio (this is controversial, the need to subdivide the varieties), monoclonal antibody leader Fuhong Hanklin, etc. (monoclonal antibody is more decentralized, the layout of the enterprise, Hai Zheng Biological, Jia and so on), growth hormone leader Changchun High-Tech, anti-allergy biopharmaceuticals leader I Wu Biological.
Four, medical services: ophthalmology leader Aier Ophthalmology, oral leading Tongce medical, CRO industry chain leader WuXi Kande, clinical CRO leader Tiger Pharmaceuticals, biological CMO leader WuXi Biological, independent laboratory leader Golden Medical, medical check-up business leader Meinian Health.
V, medical devices: medical device industry chain leader Myriad Medical, cardiac stent leader Lepu Medical, POCT leader Wanfu Biological, home medical equipment leader Yueyue Medical, chemiluminescent diagnostic reagents leader AnTu Biological, blood perfusion equipment leader Jianfan Biological.
Six, pharmaceutical business: drugstore leader Yifeng pharmacy, distribution leader Sinopharm.
Who is the real antibiotic leading stocks?
Domestic currently able to produce tigecycline pharmaceutical listed companies are Lemay Pharmaceuticals (300006), North China Pharmaceuticals (600812), Hai Zheng Pharmaceutical (600627). Mucomycin can be produced by Lianhuan Pharmaceutical (600513).
Previously, some analysts expressed their views on the incident of superbugs, saying that anti-bacteria to antibiotics, the best antibiotics are tigecycline and vancomycin, vancomycin is commonly known as the super-antibiotic, the domestic only Haizheng Pharmaceuticals (600267) and Zhejiang Pharmaceuticals (600216) production and export. But the effectiveness of vancomycin treatment has not been mentioned in the current published study results.
What are the leading stocks in the pharmaceutical and biological sector?
Pharmaceutical sector leading stocks:
1, Baiyunshan A: According to previous reports, Baiyunshan A controlling shareholder of the Guangzhou Pharmaceutical Group, joint South China Center for the creation of new medicines and a number of other scientific research institutions announced the launch of anti-"superbugs" drug research and development of the big issues, will be *** with the three major research projects: Baiyunshan Banlangen and other 10 antibacterial and anti-inflammatory traditional Chinese medicines to improve resistance to the study. Antibacterial and anti-inflammatory Chinese medicine and western antibiotics combined drug program screening; "Chinese traditional Chinese medicine against the bully" new drug research topics. However, Baiyunshan previously issued a clarification announcement, said the three major research projects, only the first major project involving the company.
2, four ring biological: due to the impact of superbugs and domestic ticks, the pharmaceutical sector has repeatedly appeared in the speculation of the trend, the disk smaller Lianhuan Pharmaceuticals for the leader, but in the Shenzhen Stock Exchange to increase the regulation of such stocks, but the pharmaceutical sector speculation has appeared to shift the signs of the history of Jiangsu securities and even the A-share history, the four-ringed biological has been quite a legend. The original name of the stock "Su Sanshan A", listed so far ten times to change the abbreviation of securities.
3, Guangzhou Pharmaceuticals: Guangzhou Pharmaceutical Group joint South China New Drug Creation Center and a number of scientific research institutions *** with the launch of the "Guangzhou Pharmaceutical Group anti-"Superbug" drug research and development of the big issues", will give play to the strengths of traditional Chinese medicine to fight against the "Superbug". Li Chuyuan, general manager of Guangzhou Pharmaceutical Group, announced that Guangzhou Pharmaceutical Group will invest the first batch of 50 million yuan as the first funding for the project, while the South China Center for the creation of new drugs will also be supporting funds for the joint project research.
4, Lianhuan Pharmaceuticals: with the help of foreign factors on the "superbug" report, the previous to Lianhuan Pharmaceuticals as the leading biopharmaceutical plate by the short-term funds of hot speculation. From a fundamental point of view, the company's performance in the past two years, although stable, but obviously lack of growth, few organizations concerned. However, the company announced that it has been unable to determine whether the company's mucin sulfate tablets and media reports can inhibit "superbugs" mucin for the same molecular structure of the drug.